SCOPE FLUIDICS SA ZY-10 Cash Flow Conversion Efficiency
SCOPE FLUIDICS SA ZY-10 cash flow conversion efficiency. Based on the latest financial reports, SCOPE FLUIDICS SA ZY-10 (S84) has a cash flow conversion efficiency ratio of -0.072x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.68 Million ≈ $-13.65 Million USD) by net assets (€162.43 Million ≈ $189.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of SCOPE FLUIDICS SA ZY-10 for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of SCOPE FLUIDICS SA ZY-10 (2021–2025)
Cash flow conversion efficiency of SCOPE FLUIDICS SA ZY-10 from 2021 to 2025. This chart illustrates how SCOPE FLUIDICS SA ZY-10's cash flow conversion efficiency has evolved over time, based on yearly financial data. View S84 stock price and chart for real-time trading data and today's change.
SCOPE FLUIDICS SA ZY-10 Cash Flow Conversion Ratio Explained
SCOPE FLUIDICS SA ZY-10 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SCOPE FLUIDICS SA ZY-10 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SCOPE FLUIDICS SA ZY-10 ranked by their cash flow conversion efficiency. Review S84 financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China New Higher Education Group Limited
F:8CN
|
0.040x |
|
ANDRADA MINING LTD.
F:9IA
|
N/A |
|
Kandi Technologies Group Inc
NASDAQ:KNDI
|
-0.359x |
|
Oil Terminal C
RO:OIL
|
0.031x |
|
Peel Mining Ltd
AU:PEX
|
-0.009x |
|
Nasmedia Co. Ltd
KQ:089600
|
-0.051x |
|
Actinogen Medical Ltd
AU:ACW
|
-0.507x |
|
Themis Medicare Limited
NSE:THEMISMED
|
-0.004x |
Annual Cash Flow Conversion Efficiency for SCOPE FLUIDICS SA ZY-10 (2021–2025)
The table below shows the annual cash flow conversion efficiency of SCOPE FLUIDICS SA ZY-10 from 2021 to 2025. Also see SCOPE FLUIDICS SA ZY-10 (S84) total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €162.43 Million ≈ $189.90 Million |
€-46.11 Million ≈ $-53.91 Million |
-0.284x | -65.50% |
| 2024-12-31 | €146.35 Million ≈ $171.10 Million |
€-25.10 Million ≈ $-29.35 Million |
-0.172x | +27.15% |
| 2023-12-31 | €80.93 Million ≈ $94.62 Million |
€-19.06 Million ≈ $-22.28 Million |
-0.235x | -178.45% |
| 2022-12-31 | €332.97 Million ≈ $389.28 Million |
€-28.16 Million ≈ $-32.92 Million |
-0.085x | +97.33% |
| 2021-12-31 | €6.74 Million ≈ $7.88 Million |
€-21.37 Million ≈ $-24.98 Million |
-3.171x | -- |
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.